EGFR and non-small cell lung carcinoma: Our findings suggest that NSCLC patients could be classified as having EGFR-activating mutations or wild-type EGFR according to our nomogram, indicating that the nomogram could be used as a novel and user-friendly instrument for the better management of NSCLC patients.